DHR
Danaher Corporation · Healthcare
Danaher Corporation · Healthcare
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization; microscopes; genomics consumables; and Gene and Cell Therapy. This segment also offers bioprocess technologies, consumables, and services; and filtration, separation, and purification technologies to the pharmaceutical and biopharmaceutical, food and beverage, medical, and life sciences companies, as well as universities, medical schools and research institutions, and various industrial manufacturers. The Diagnostics segment provides chemistry, immunoassay, microbiology, and automation systems, as well as hematology, molecular, acute care, and pathology diagnostics products. This segment offers clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The Environmental & Applied Solutions segment offers instrumentation, consumables, software, services, and disinfection systems to analyze, treat, and manage ultra-pure, potable, industrial, waste, ground, source, and ocean water in residential, commercial, industrial, and natural resource applications. This segment also provides instruments, software, services, and consumables for various color and appearance management, packaging design and quality management, packaging converting, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is headquartered in Washington, the District of Columbia.
Healthcare
Medical - Diagnostics & Research
61,000
1978-12-29
0.99

Fulton Breakefield Broenniman LLC lowered its position in Danaher Corporation (NYSE: DHR) by 27.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 48,301 shares of the conglomerate's stock after selling 18,647 shares during the quarter. Fulton Breakefield Broenniman LLC's holdings

Danaher is an American healthcare company that manufactures and markets products used for advances in biotechnology, life sciences, and diagnostics. Danaher has increased its dividend for 13 consecutive years. And its dividend growth has been nothing short of spectacular. DHR has a strong financial position. Its long-term debt/equity ratio is 0.3, while the interest coverage ratio is 17.

Runnymede Capital Advisors Inc. bought a new position in Danaher Corporation (NYSE: DHR) in the fourth quarter, according to its most recent disclosure with the SEC. The firm bought 3,658 shares of the conglomerate's stock, valued at approximately $837,000. Several other institutional investors and hedge funds have also recently modified their holdings of

Ascent Group LLC increased its position in Danaher Corporation (NYSE: DHR) by 28.4% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 12,723 shares of the conglomerate's stock after acquiring an additional 2,811 shares during the period. Ascent Group LLC's

FNY Investment Advisers LLC grew its holdings in Danaher Corporation (NYSE: DHR) by 16,106.9% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 4,700 shares of the conglomerate's stock after acquiring an additional 4,671 shares during the period. FNY Investment

Defender Capital LLC. acquired a new stake in shares of Danaher Corporation (NYSE: DHR) during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm acquired 156,015 shares of the conglomerate's stock, valued at approximately $35,715,000. Danaher makes up about 11.6% of Defender
Leiken Jonathan
officer: SVP-Chief Legal Officer
2,374 SH @ $0.00
2026-03-01
Leiken Jonathan
officer: SVP-Chief Legal Officer
6,416 SH @ $210.64
2026-03-01
McGrew Matthew
officer: Executive Vice President
5,935 SH @ $0.00
2026-03-01
McGrew Matthew
officer: Executive Vice President
16,039 SH @ $210.64
2026-03-01
Milosevich Gregory M
officer: Executive Vice President
11,548 SH @ $210.64
2026-03-01
Milosevich Gregory M
officer: Executive Vice President
4,273 SH @ $0.00
2026-03-01
Milosevich Gregory M
officer: Executive Vice President
118 SH @ $210.64
2026-03-01
Bouda Christopher
officer: VP, Chief Accounting Officer
1,247 SH @ $0.00
2026-03-01